Announcements
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.60 |
---|---|
High | 3.60 |
Low | 3.60 |
Bid | 3.32 |
Offer | 3.44 |
Previous close | 3.60 |
Average volume | 828.89 |
---|---|
Shares outstanding | 26.29m |
Free float | 18.78m |
P/E (TTM) | -- |
Market cap | 102.79m USD |
EPS (TTM) | -1.58 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼